Stockreport

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

Alkermes plc - Ordinary Shares  (ALKS) 
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
PDF DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and [Read more]